{"filing":{"accession_number":"0001664710-26-000048","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"kros-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/kros-20260803.htm"},"events":[{"id":23447,"run_id":21198,"accession_number":"0001664710-26-000048","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $28.7 million, R\u0026D expenses of $22.3 million, cash position of $257.6 million, and cash runway guidance into H1 2028. The filing explicitly states the press release was issued on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, with condensed consolidated financial statements attached.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23668,"accession_number":"0001664710-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $28.7 million, R\u0026D expenses of $22.3 million, cash position of $257.6 million, and cash runway guidance into H1 2028. The filing explicitly states the press release was issued on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, with condensed consolidated financial statements attached.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:25.682403+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23668,"accession_number":"0001664710-26-000048","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $28.7 million, R\u0026D expenses of $22.3 million, cash position of $257.6 million, and cash runway guidance into H1 2028. The filing explicitly states the press release was issued on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, with condensed consolidated financial statements attached.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:25.682403+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-08-03"}]}